GlaxoSmithKline backs a preclinical acne treatment from Eligo Bioscience that uses CRISPR to kill bacteria
Roughly three and a half years since bagging a $20 million financing round to develop its CRISPR-based microbiome modulation platform, Eligo Bioscience has made …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.